Pfizer and Bristol-Myers Squibb’s oral anticoagulant apixaban achieved positive results in the late-stage Advance-2 study. Apixaban was shown to be statistically superior to 40 mg once daily enoxaparin (Lovenox) in reducing the incidence of venous thromboembolism in patients undergoing total knee replacement surgery. The study results also showed lower rates of bleeding in patients treated with apixaban compared to enoxaparin. Apixaban is an oral, highly selective Factor Xa inhibitor, p...